Diagnostic Value of Serum Biomarkers for Patients Undergoing Curative Resection with Non-B, Non-C Hepatocellular Carcinoma

Li, Youdi; Chen, Yanfei; Chen, Jiu

doi:10.29271/jcpsp.2020.02.134

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, more advanced primary tumor stages were observed in patients with NBNC-HCC in this study. This result is consistent with past reports (3,5,8,(21)(22)(23)(24). This may be due to the lack of systematic surveillance of potential candidates for NBNC-HCC resection compared with HBV-HCC and HCV-HCC resection.…”

Section: Discussionsupporting

confidence: 93%

Clinical characteristics, prognosis, and surgical outcomes of patients with NBNC hepatocellular carcinoma: three-decade observational study

Yasukawa

Shimizu

Koyama

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: The incidence of non-hepatitis B virus, non-hepatitis C virus hepatocellular carcinoma (NBNC-HCC) is increasing worldwide. We assessed the clinical characteristics and surgical outcomes of NBNC-HCC, versus hepatitis B (HBV-HCC) and hepatitis C (HCV-HCC). Methods: Etiologies, fibrosis stages, and survival outcomes were analyzed of 789 consecutive patients who underwent surgery from 1990 to 2020 (HBV-HCC, n=149; HCV-HCC, n=424; NBNC-HCC, n=216). Results:The incidence of hypertension and diabetes mellitus was significantly higher in patients with NBNC-HCC than in those with HBV-HCC and HCV-HCC. Significantly more advanced tumor stages were observed in patients with NBNC-HCC; however, better liver function and lower fibrosis stages were observed. Patients with NBNC-HCC had significantly worse 5-year overall survival than patients with HBV-HCC; overall survival was comparable between patients with NBNC-HCC and HCV-HCC. Patients with HCV-HCC had significantly worse 5-year recurrence-free survival than patients with HBV-HCC and NBNC-HCC. In patients with NBNC-HCC, overall survival was comparable among three periods (1990–2000, 2001–2010, and 2011–2020) despite significant improvement in patients with HBV-HCC and HCV-HCC. Conclusion: The prognosis of NBNC-HCC was similar to that of HBV-HCC and HCV-HCC regardless of tumor progression at surgery. Patients with hypertension, diabetes mellitus, and dyslipidemia require careful systematic follow-up and treatment.

show abstract

Section: Discussionsupporting

confidence: 93%

Clinical characteristics, prognosis, and surgical outcomes of patients with NBNC hepatocellular carcinoma: three-decade observational study

Yasukawa

Shimizu

Koyama

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this has not been shown in any studies before. Additionally, AFP and PIVKA-II models display excellent performance in distinguishing resected tumor HCC (Additional file 6: Table S6 ), comparable to the observation of Li Y [ 8 ].…”

Section: Discussionsupporting

confidence: 55%

The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma

Tran,

Phan,

Nguyen

et al. 2023

BMC Res Notes

View full text Add to dashboard Cite

Objective This study aims to describe the diagnostic performance of alpha-fetoprotein (AFP), alpha-fetoprotein L3 isoform (AFP-L3), protein induced by vitamin K absence II (PIVKA-II), and combined biomarkers for non-B non-C hepatocellular carcinoma (NBNC-HCC). Results A total of 681 newly-diagnosed primary liver disease subjects (385 non-HCC, 296 HCC) who tested negativity for the hepatitis B surface antigen (HBsAg) and hepatitis C antibody (anti-HCV) enrolled in this study. At the cut-off point of 3.8 ng/mL, AFP helps to discriminate HCC from non-HCC with an area under the curve (AUC) value of 0.817 (95% confidence interval [CI]: 0.785–0.849). These values of AFP-L3 (cut-off 0.9%) and PIVKA-II (cut-off 57.7 mAU/mL) were 0.758 (95%CI: 0.725–0.791) and 0.866 (95%CI: 0.836–0.896), respectively. The Bayesian Model Averaging (BMA) statistic identified the optimal model, including patients’ age, aspartate aminotransferase, AFP, and PIVKA-II combination, which helps to classify HCC with better performance (AUC = 0.896, 95%CI: 0.872–0.920, P < 0.001). The sensitivity and specificity of the optimal model reached 81.1% (95%CI: 76.1–85.4) and 83.2% (95%CI: 78.9–86.9), respectively. Further analyses indicated that AFP and PIVKA-II markers and combined models have good-to-excellent performance detecting curative resected HCC, separating HCC from chronic hepatitis, dysplastic, and hyperplasia nodules.

show abstract

Clinical characteristics, prognosis, and surgical outcomes of patients with non-HBV and non-HCV related hepatocellular carcinoma: three-decade observational study

et al. 2023

View full text Add to dashboard Cite

Background The incidence of non-hepatitis B virus, non-hepatitis C virus hepatocellular carcinoma (non-B non-C-HCC) is increasing worldwide. We assessed the clinical characteristics and surgical outcomes of non-B non-C-HCC, versus hepatitis B (HBV-HCC) and hepatitis C (HCV-HCC). Methods Etiologies, fibrosis stages, and survival outcomes were analyzed of 789 consecutive patients who underwent surgery from 1990 to 2020 (HBV-HCC, n = 149; HCV-HCC, n = 424; non-B non-C-HCC, n = 216). Results The incidence of hypertension and diabetes mellitus was significantly higher in patients with NON-B NON-C-HCC than in those with HBV-HCC and HCV-HCC. Significantly more advanced tumor stages were observed in patients with non-B non-C-HCC; however, better liver function and lower fibrosis stages were observed. Patients with non-B non-C-HCC had significantly worse 5-year overall survival than patients with HBV-HCC; overall survival was comparable between patients with non-B non-C-HCC and HCV-HCC. Patients with HCV-HCC had significantly worse 5-year recurrence-free survival than patients with HBV-HCC and non-B non-C-HCC. In patients with non-B non-C-HCC, overall survival was comparable among three periods (1990–2000, 2001–2010, and 2011–2020) despite significant improvement in patients with HBV-HCC and HCV-HCC. Conclusion The prognosis of non-B non-C-HCC was similar to that of HBV-HCC and HCV-HCC regardless of tumor progression at surgery. Patients with hypertension, diabetes mellitus, and dyslipidemia require careful systematic follow-up and treatment.

show abstract

Diagnostic Value of Serum Biomarkers for Patients Undergoing Curative Resection with Non-B, Non-C Hepatocellular Carcinoma

Abstract: Objective: To determine the diagnostic value of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) for patients with non-B, non-C hepatocellular carcinoma (NBNC HCC).

Cited by 3 publications

References 24 publications

Clinical characteristics, prognosis, and surgical outcomes of patients with NBNC hepatocellular carcinoma: three-decade observational study

Clinical characteristics, prognosis, and surgical outcomes of patients with NBNC hepatocellular carcinoma: three-decade observational study

The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma

Clinical characteristics, prognosis, and surgical outcomes of patients with non-HBV and non-HCV related hepatocellular carcinoma: three-decade observational study

Contact Info

Product

Resources

About